clinical trial · NCT07219511
A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
HeartHeart Failure With Preserved Ejection Fraction (HFPEF)VS-041Placebo
brief summary
A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants with Heart Failure with Preserved Ejection Fraction (HFpEF)
started
Nov 4, 2025
primary completion
Jun 1, 2026
completion
Jul 1, 2026
last updated
Apr 9, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol